Alzamend Neuro
ALZN
19 hedge funds and large institutions have $1.66M invested in Alzamend Neuro in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 9 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
27% more funds holding
Funds holding: 15 → 19 (+4)
14% more call options, than puts
Call options by funds: $789K | Put options by funds: $692K
0% more ownership
Funds ownership: 0% → 0% (+0%)
16% less capital invested
Capital invested by funds: $1.99M → $1.66M (-$325K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$374K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$266K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$251K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$152K |
| 5 |
MFG
Merit Financial Group
Alpharetta,
Georgia
|
+$114K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$533K |
| 2 |
SCA
Sassicaia Capital Advisers
Jericho,
New York
|
-$289K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$157K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$144K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$105K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSA
26
Schonfeld Strategic Advisors
New York
| – | -$97K | -23 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$82K | -20 | Closed |
|
|
WAM
28
Warberg Asset Management
Winnetka,
Illinois
| – | -$43K | -10 | Closed |
|
29
JP Morgan Chase
New York
| – | -$3K | -1 | Closed |
|
30
Morgan Stanley
New York
| – | -$1K | – | – |
|
ALZN Hedge Fund Activity: Q4 2021 in Review
19 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q4 2021, worth a combined $1.66M — down 16% from $1.99M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ALZN positions and 9 closed out — a net gain of 4 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $374K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $533K sold.
- 19 institutional investors held Alzamend Neuro (ALZN) as of Q4 2021, up from 15 in Q3 2021.
- Funds reported $1.66M of Alzamend Neuro stock for Q4 2021, down 16% quarter-over-quarter.
- 13 funds opened new Alzamend Neuro positions in Q4 2021 and 9 closed out, a net change of +4 holders.
- The largest Alzamend Neuro buyer in Q4 2021 was Marshall Wace, an estimated $374K added.
- The largest Alzamend Neuro seller in Q4 2021 was Two Sigma Investments, an estimated $533K sold.
Based on aggregated 13F filings for Q4 2021.